Pasar al contenido principal

DESARROLLO, FUNCION INMUNE Y EFICACIA DE CANDIDATOS VACUNALES FRENTE AL SARS-COV-2/COVID-19 BASADOS EN EL VECTOR POXVIRUS MVA

PID2020-114481RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice

  • Lázaro-Frías, Adrián
  • Pérez Ramírez, Patricia
  • Zamora, Carmen
  • Sánchez-Cordón, Pedro J.
  • Guzmán, María
  • Luczkowiak, Joanna
  • Delgado, Rafael
  • Casasnovas, José María
  • Esteban, Mariano
  • García-Arriaza, Juan
Two doses of the MVA-CoV2-S vaccine candidate expressing the SARS-CoV-2 spike (S) protein protected K18-hACE2 transgenic mice from a lethal dose of SARS-CoV-2. This vaccination regimen prevented virus replication in the lungs, reduced lung pathology, and diminished levels of pro-inflammatory cytokines. High titers of IgG antibodies against S and receptor-binding domain (RBD) proteins and of neutralizing antibodies were induced against parental virus and variants of concern, markers that correlated with protection. Similar SARS-CoV-2-specific antibody responses were observed at prechallenge and postchallenge in the two-dose regimen, while the single-dose treatment does not avoid vaccine breakthrough infection. All vaccinated animals survived infection and were also protected to SARS-CoV-2 reinfection. Furthermore, two MVA-CoV2-S doses induced long-term memory S-specific humoral and cellular immune responses in C57BL/6 mice, 6 months after immunization. The efficacy and immunological benefits of the MVA-CoV2-S vaccine candidate against COVID-19 supports its consideration for human clinical trials., This research was supported by Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 (Crue Universidades-Banco Santander) grant and CSIC grant 202120E079 (to J.G.-A.), CSIC grant 2020E84, La CaixaImpulse grant CF01-00008, Ferrovial and MAPFRE donations (to M.E.) and MICINN, Spanish Research Agency grant PID2020-114481RB-I00 (to J.G.-A. and M.E.). This research work was also funded by the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to J.G.-A. and M.E.). J.M.C. acknowledges MICINN and CSIC support (project number 202020E079). R.D. received grants from the European Commission Horizon 2020 Framework Programme: Project VIRUSCAN FETPROACT-2016: 731868 and EPIC-CROWN-2-2021:101046084, and Fundación Caixa-Health Research HR18-00469 (Project StopEbola). We thank the Spanish Research Council (CSIC) and the Spanish Ministry of Science and Innovation (MICINN) for continuous support. We thank Centro de Investigación en Sanidad Animal (CISA)-Instituto Nacional de Investigaciones Agrarias (INIA-CSIC) (Valdeolmos, Madrid, Spain) for the BSL-3 facilities. SARS-CoV-2 MAD6 virus isolate was kindly provided by José M. Honrubia and Dr. Luis Enjuanes (CNB-CSIC, Madrid, Spain). We thank Carlos Óscar Sánchez Sorzano (CNB-CSIC, Madrid, Spain) for help with the statistical analysis. We thank the Histology Facility at CNB-CSIC for the histological preparation of biological samples., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection

  • Pérez Ramírez, Patricia
  • Lázaro-Frías, Adrián
  • Zamora, Carmen
  • Sánchez-Cordón, Pedro J.
  • Astorgano, David
  • Luczkowiak, Joanna
  • Delgado, Rafael
  • Casasnovas, José María
  • Esteban, Mariano
  • García-Arriaza, Juan
We generated an optimized COVID-19 vaccine candidate based on the modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein, termed MVA-CoV2-S(3P). The S(3P) protein was expressed at higher levels (2-fold) than the non-stabilized S in cells infected with the corresponding recombinant MVA viruses. One single dose of MVA-CoV2-S(3P) induced higher IgG and neutralizing antibody titers against parental SARS-CoV-2 and variants of concern than MVA-CoV2-S in wild-type C57BL/6 and in transgenic K18-hACE2 mice. In immunized C57BL/6 mice, two doses of MVA-CoV2-S or MVA-CoV2-S(3P) induced similar levels of SARS-CoV-2-specific B- and T-cell immune responses. Remarkably, a single administration of MVA-CoV2-S(3P) protected all K18-hACE2 mice from morbidity and mortality caused by SARS-CoV-2 infection, reducing SARS-CoV-2 viral loads, histopathological lesions, and levels of pro-inflammatory cytokines in the lungs. These results demonstrated that expression of a novel full-length prefusion-stabilized SARS-CoV-2 S protein by the MVA poxvirus vector enhanced immunogenicity and efficacy against SARS-CoV-2 in animal models, further supporting MVA-CoV2-S(3P) as an optimized vaccine candidate for clinical trials., This research was supported by Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII), Fondo COVID-19 grant COV20/00151, Fondo Supera COVID-19 (Crue Universidades-Banco Santander) grant and Spanish Research Council (CSIC) grant 202120E079 (to JG-A), CSIC grant 2020E84, La CaixaImpulse grant CF01-00008, Ferrovial and MAPFRE donations (to ME), and Spanish Ministry of Science and Innovation (MICINN), Spanish Research Agency grant PID2020-114481RB-I00 (to JG-A and ME). This research work was also funded by the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JC acknowledges MICINN and CSIC support (project number 202020E079). RD received grants from the European Commission Horizon 2020 Framework Programme: Project VIRUSCAN FETPROACT-2016: 731868 and EPIC-CROWN-2-2021:101046084, and Fundación Caixa-Health Research HR18-00469 (Project StopEbola)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters

  • Boudewijns, Robbert
  • Pérez Ramírez, Patricia
  • Lázaro-Frías, Adrián
  • Van Looveren, Dominique
  • Vercruysse, Thomas
  • Thibaut, Hendrik Jan
  • Weynand, Birgit
  • Coelmont, Lotte
  • Neyts, Johan
  • Astorgano, David
  • Montenegro, Dolores
  • Puentes, Eugenia
  • Rodríguez, Esteban
  • Dallmeier, Kai
  • Esteban, Mariano
  • García-Arriaza, Juan
To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials., The authors declare that this study received funding from Fondo COVID-19 grant COV20/00151 [Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)], Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander) and Spanish Research Council (CSIC) grant 202120E079 (to JG-A), CSIC grant 2020E84, La CaixaImpulse grant CF01-00008, Ferrovial and MAPFRE donations (to ME), a Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RB-I00 to JGA and ME), and internal funding from KU Leuven. This research work was also funded by the European Commission-NextGeneration EU through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2

  • Mooij, Petra
  • García-Arriaza, Juan
  • Pérez Ramírez, Patricia
  • Lázaro-Frías, Adrián
  • Verstrepen, Babs E.
  • Böszörményi, Kinga P.
  • Mortier, Daniella
  • Fagrouch, Zahra
  • Kiemenyi-Kayere, Gwendoline
  • Niphuis, Henk
  • Acar, Roja Fidel
  • Meijer, Lisette
  • Stammes, Marieke A.
  • Kondova, Ivanela
  • Verschoor, Ernst J.
  • GeurtsvanKessel, Corine H.
  • Bruin, Erwin de
  • Sikkema, Reina S.
  • Luczkowiak, Joanna
  • Delgado, Rafael
  • Montenegro, Dolores
  • Puentes, Eugenia
  • Rodríguez, Esteban
  • Bogers, Willy M. J. M.
  • Koopman, Gerrit
  • Esteban, Mariano
Novel safe, immunogenic, and effective vaccines are needed to control the COVID-19 pandemic, caused by SARS-CoV-2. Here, we describe the safety, robust immunogenicity, and potent efficacy elicited in rhesus macaques by a modified vaccinia virus Ankara (MVA) vector expressing a full-length SARS-CoV-2 spike (S) protein (MVA-S). MVA-S vaccination was well tolerated and induced S and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against SARS-CoV-2 and several variants of concern. S-specific IFNγ, but not IL-4, -producing cells were also elicited. After SARS-CoV-2 challenge, vaccinated animals showed a significant strong reduction of virus loads in bronchoalveolar lavages (BAL) and decreased levels in throat and nasal mucosa. Remarkably, MVA-S also protected macaques from fever and infection-induced cytokine storm. Computed tomography and histological examination of the lungs showed reduced lung pathology in MVA-S-vaccinated animals. These findings favor the use of MVA-S as a potential vaccine for SARS-CoV-2 in clinical trials., This research was supported by Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), and Spanish Research Council (CSIC) grant 202120E079 (to JG-A); CSIC grant 2020E84, la Caixa Banking Foundation grant CF01-00008, Ferrovial, and MAPFRE donations (to ME); a Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RB-I00; to JG-A and ME); and internal funding from the BPRC. This research work was also funded by the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). RD received grants from the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016: 731868 and Project EPIC-CROWN-2: 101046084), and Fundación Caixa-Health Research HR18-00469 (Project StopEbola)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

MVA-CoV2-S vaccine candidate confers full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice

  • Villadiego, Javier
  • García-Arriaza, Juan
  • Ramírez Lorca, Reposo
  • Cabello-Rivera, Daniel
  • Álvarez-Vergara, María I.
  • Cala-Fernández, Fernando
  • García-Swinburn, Roberto
  • García-Roldán, Ernesto
  • López-Ogáyar, Juan L.
  • Zamora, Carmen
  • Astorgano, David
  • Pérez Ramírez, Patricia
  • Rosales-Nieves, Alicia E.
  • Muñoz-Cabello, Ana M.
  • Pascual Bravo, Alberto
  • Esteban, Mariano
  • López-Barneo, José
  • Toledo-Aral, Juan José
The protective efficacy of vaccines against SARS-CoV-2 infection in the brain is yet unclear. Here, in the susceptible transgenic K18-hACE2 mouse model of severe COVID-19 disease, we report a detailed spatiotemporal description of the SARS-CoV-2 infection and replication in different areas of the brain. Remarkably, SARS-CoV-2 brain replication occurs primarily in neurons, producing important neuropathological alterations such as neuronal loss, incipient signs of neuroinflammation, and vascular damage in SARS-CoV-2 infected mice. Notably, one or two doses of a modified vaccinia virus Ankara (MVA) vector expressing the SARS-CoV-2 spike (S) protein (MVA-CoV2-S) conferred full protection against SARS-CoV-2 cerebral infection, preventing virus replication in all areas of the brain and its associated damage. This protection was maintained even after SARS-CoV-2 reinfection. To our knowledge, this is the first study of a COVID-19 vaccine candidate showing 100% efficacy against SARS-CoV-2 brain infection and damage, reinforcing the use of MVA-CoV2-S as a promising vaccine candidate against SARS-CoV-2/COVID-19, worth to move forward into clinical trials., The authors thank the Centro de Investigación en Sanidad Animal (CISA)-Instituto Nacional de Investigaciones Agrarias (INIA-CSIC) (Valdeolmos, Madrid, Spain) for the BSL-3 facilities. SARS-CoV-2 MAD6 virus isolate was kindly provided by José M. Honrubia and Dr. Luis Enjuanes (CNB-CSIC, Madrid, Spain). We also thank to Dr. Konstantin L. Levitsky for excellent technical assistance with the confocal acquisition. We thank the Spanish Research Council (CSIC) and the Spanish Ministry of Science and Innovation (MICINN) for continuous support. This research was supported by MCIN/Spanish Research Agency (AEI)/ 10.13039/501100011033 grants: PID2019-105995RB-I00 (J.T.-A. and J.V.), PID2020- 114481RB-I00 (J.G.-A. and M.E.), and PID2019-106410RB-I00 (J.L.-B.). Moreover, this research work was also funded by Red TerCel ISCIII, RD16/0011/0025 (J.T.-A.); Consejería de Salud y Familias, Junta de Andalucía Grant, PECOVID-0078-2020 (R.R.-L. and J.V.); Fondo COVID-19 grant COV20/00151 [Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)], Fondo Supera COVID-19 (Crue Universidades-Banco Santander) grant and CSIC grant 202120E079 (J.G.-A.); and CSIC grant 2020E84, La CaixaImpulse grant CF01-00008, Ferrovial and MAPFRE donations (M.E.). Additionally, we have also funding from the European Commission-NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) (J.G.-A. and M.E.) and the European Research Council (ERC Advanced Grant PRJ201502629) (J.L.-B.)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate

  • Villadiego, Javier
  • García-Arriaza, Juan
  • Ramírez Lorca, Reposo
  • García-Swinburn, Roberto
  • Cabello-Rivera, Daniel
  • Rosales-Nieves, Alicia E.
  • Álvarez-Vergara, María I.
  • Cala-Fernández, Fernando
  • García-Roldán, Ernesto
  • López-Ogáyar, Juan L.
  • Zamora, Carmen
  • Astorgano, David
  • Albericio, Guillermo
  • Pérez Ramírez, Patricia
  • Muñoz-Cabello, Ana M.
  • Pascual Bravo, Alberto
  • Esteban, Mariano
  • López-Barneo, José
  • Toledo-Aral, Juan José
Vaccines against SARS-CoV-2 have been shown to be safe and effective but their protective efficacy against infection in the brain is yet unclear. Here, in the susceptible transgenic K18-hACE2 mouse model of severe coronavirus disease 2019 (COVID-19), we report a spatiotemporal description of SARS-CoV-2 infection and replication through the brain. SARS-CoV-2 brain replication occurs primarily in neurons, leading to neuronal loss, signs of glial activation and vascular damage in mice infected with SARS-CoV-2. One or two doses of a modified vaccinia virus Ankara (MVA) vector expressing the SARS-CoV-2 spike (S) protein (MVA-CoV2-S) conferred full protection against SARS-CoV-2 cerebral infection, preventing virus replication in all areas of the brain and its associated damage. This protection was maintained even after SARS-CoV-2 reinfection. These findings further support the use of MVA-CoV2-S as a promising vaccine candidate against SARS-CoV-2/COVID-19., We thank the CSIC and the Spanish Ministry of Science and Innovation for continuous support. This research was supported by the Spanish Ministry of Science and Innovation/Spanish Research Agency/10.13039/501100011033 grant nos. PID2019-105995RB-I00 (J.J.T.-A. and J.V.), PID2020-114481RB-I00 (J.G.-A. and M.E.), RTI2018-096629-B-I00 (A.P.) and PID2019-106410RB-I00 (J.L.-B.). Moreover, this research was also funded by Red TerCel ISCIII (no. RD16/0011/0025 to J.J.T.-A.), Consejería de Economía, Conocimiento, Empresas y Universidad US-1380891 (to J.J.T.-A. and J.V.), Consejería de Salud y Familias, Junta de Andalucía grant no. PECOVID-0078-2020 (to R.R.-L. and J.V.), Consejería de Educación y Deporte, Junta de Andalucía grant no. PY20_01312 (to A.P.), Fondo COVID-19 grant no. COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III), Fondo Supera COVID-19 (Crue Universidades-Banco Santander) grant and CSIC grant no. 202120E079 (J.G.-A.), CSIC grant no. 2020E84, La CaixaImpulse grant no. CF01-00008 and Ferrovial and MAPFRE donations (to M.E.). Additionally, we received funding from the European Commission-NextGenerationEU, through the CSIC’s Global Health Platform (PTI Salud Global) (to J.G.-A. and M.E.) and the European Research Council (ERC Advanced grant no. PRJ201502629) (to J.L.-B.). J.G.-A. and M.E. also acknowledge financial support from the Spanish State Research Agency (no. AEI/10.13039/501100011033) through the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (nos. SEV-2013-0347 and SEV-2017-0712). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy

  • Lennol, Matthew P.
  • García-Ayllón, María-Salud
  • Esteban, Mariano
  • García-Arriaza, Juan
  • Sáez-Valero, Javier
Various species of the SARS-CoV-2 host cell receptor, the angiotensin-converting enzyme 2 (ACE2), are present in serum, which may result from virus entry and subsequent proteolytic processing of the membrane receptor. We have recently demonstrated changes of particular ACE2 species in virus infected humans, either cleaved fragments or circulating full-length species. Here, we further explore the potential of serum ACE2 as a biomarker to test SARS-CoV-2 infection and vaccine efficacy in virus susceptible transgenic K18-hACE2 mice expressing human ACE2. First, in serum samples derived from K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2, we observed an increase in the levels of cleaved ACE2 fragment at day 2 post-challenge, which may represent the subsequent proteolytic processing through virus entry. These elevated levels were maintained until the death of the animals at day 6 post-challenge. The circulating full-length ACE2 form displayed a sizable peak at day 4, which declined at day 6 post-challenge. Noticeably, immunization with two doses of the MVA-CoV2-S vaccine candidate prevented ACE2 cleaved changes in serum of animals challenged with a lethal dose of SARS-CoV-2. The efficacy of the MVA-CoV2-S was extended to vaccinated mice after virus re-challenge. These findings highlight that ACE2 could be a potential serum biomarker for disease progression and vaccination against SARS-CoV-2., This study was funded in part by the Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL; grant 2020-0308), the Direcció General de Ciència I Investigació, Generalitat Valenciana (AICO/2021/308), and by the Instituto de Salud Carlos III (ISCIII, grants PI19-01359), co-financed by the Fondo Europeo de Desarrollo Regional (FEDER, “Investing in your future”) and through CIBERNED, ISCIII. We also acknowledge financial support from the Spanish Ministerio de Economía y Competitividad, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2017-0723). This research was also supported by Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), and Spanish Research Council (CSIC) grant 202120E079 (to JG-A); CSIC grant 2020E84, Ferrovial, and MAPFRE donations (to ME); and Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RB-I00; to JG-A and ME). This research work was also funded by the European Commission- NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). MPL is supported by a BEFPI scholarship from the Generalitat Valenciana. JGA and ME acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies

  • Aparicio, Belén
  • Ruiz, Marta
  • Casares, Noelia
  • Silva, Leyre
  • Egea, Josune
  • Pérez Ramírez, Patricia
  • Albericio, Guillermo
  • Esteban, Mariano
  • García-Arriaza, Juan
  • Lasarte, Juan José
  • Sarobe, Pablo
Current vaccines against SARS-CoV-2, based on the original Wuhan sequence, induce antibodies with different degrees of cross-recognition of new viral variants of concern. Despite potent responses generated in vaccinated and infected individuals, the Omicron (B.1.1.529) variant causes breakthrough infections, facilitating viral transmission. We previously reported a vaccine based on a cyclic peptide containing the 446-488 S1 sequence (446-488cc) of the SARS-CoV-2 spike (S) protein from Wuhan isolate. To provide the best immunity against Omicron, here we compared Omicron-specific immunity induced by a Wuhanbased 446-488cc peptide, by a Wuhan-based recombinant receptor-binding domain (RBD) vaccine and by a new 446-488cc peptide vaccine based on the Omicron sequence. Antibodies induced by Wuhan peptide 446-488cc in three murine strains not only recognized the Wuhan and Omicron 446-488 peptides similarly, but also Wuhan and Omicron RBD protein variants. By contrast, antibodies induced by the Wuhan recombinant RBD vaccine showed a much poorer cross-reactivity for the Omicron RBD despite similar recognition of Wuhan and Omicron peptide variants. Finally, although the Omicron-based 446-488cc peptide vaccine was poorly immunogenic in mice due to the loss of T cell epitopes, co-immunization with Omicron peptide 446-488cc and exogenous T cell epitopes induced strong cross-reactive antibodies that neutralized Omicron SARS-CoV-2 virus. Since mutations occurring within this sequence do not alter T cell epitopes in humans, these results indicate the robust immunogenicity of 446-488cc-based peptide vaccines that induce antibodies with a high crossrecognition capacity against Omicron, and suggest that this sequence could be included in future vaccines targeting the Omicron variant., This work was supported by Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional “Una manera de hacer Europa” under grant PI20/00260, Gobierno de Navarra under grant 0011- 3597-2020-000024 to PS and by Paula & Rodger Riney Foundation to JJL. This research was also supported by Spanish Research Council (CSIC) grants 202120E079 (to JG-A) and 2020E84 (to ME), Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RBI00; to JG-A and ME), and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to JG-A). This research work was also funded by the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A and ME also acknowledge financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV- 2017-0712)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

  • Lázaro-Gorines, Rodrigo
  • Pérez Ramírez, Patricia
  • Heras-Murillo, Ignacio
  • Adán-Barrientos, Irene
  • Albericio, Guillermo
  • Astorgano, David
  • Flores, Sara
  • Luczkowiak, Joanna
  • Labiod, Nuria
  • Harwood, Seandean Lykke
  • Segura-Tudela, Alejandro
  • Rubio-Pérez, Laura
  • Nugraha, Yudhi
  • Shang, Xiaoran
  • Li, Yuxing
  • Alfonso, Carlos
  • Adipietro, Kaylin A.
  • Abeyawardhane, Dinendra L.
  • Navarro, Rocío
  • Compte, Marta
  • Yu, Wenbo
  • MacKerell Jr., Alexander D.
  • Sanz, Laura
  • Weber, David J.
  • Blanco, Francisco J.
  • Esteban, Mariano
  • Pozharski, Edwin
  • Godoy-Ruiz, Raquel
  • Muñoz, Inés G.
  • Delgado, Rafael
  • Sancho, David
  • García-Arriaza, Juan
  • Álvarez-Vallina, Luis
17 p.-4 fig., Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS-CoV-2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross-priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TNT, are first generated by grafting an anti-RBD biparatopic tandem nanobody onto a trimerbody scaffold. Cryo-EM data show that the TNT structure allows simultaneous binding to all six RBD epitopes, demonstrating a high-avidity neutralizing interaction. Then, by C-terminal fusion of an anti-DNGR-1 scFv to TNT, the bispecific trimerbody TNTDNGR-1 is generated to target neutralized virions to type 1 conventional DCs (cDC1s) and promote T cell cross-priming. Therapeutic administration of TNTDNGR-1, but not TNT, protects K18-hACE2 mice from a lethal SARS-CoV-2 infection, boosting virus-specific humoral responses and CD8+ T cell responses. These results further strengthen the central role of interactions with immune cells in the virus-neutralizing antibody activity and demonstrate the therapeutic potential of the Fc-free strategy that can be used advantageously to provide both immediate and long-term protection against SARS-CoV-2 and other viral infections., SARS-CoV-2 B.1.351 and B.1.167.2 viruses used in this study were obtained through the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 653316. SARS-CoV-2 B.1 (MAD6 isolate) was kindly provided by José M. Honrubia and Luis Enjuanes (CNB-CSIC, Madrid, Spain). The authors thank Centro de Investigación en Sanidad Animal (CISA)-Instituto Nacional de Investigaciones Agrarias (INIA-CSIC) (Valdeolmos, Madrid, Spain) for the BSL-3 facilities. Research in LA-V laboratory was funded by the BBVA Foundation (Ayudas Fundación BBVA a Equipos de Investigación Científica SARS-CoV-2 y COVID-19); the MCIN/AEI/10.13039/501100011033 (PID2020-117323RB-I00 and PDC2021-121711-I00), partially supported by the European Regional Development Fund (ERDF); the Carlos III Health Institute (ISCIII) (DTS20/00089), partially supported by the ERDF, the Spanish Association Against Cancer (AECC 19084); the CRIS Cancer Foundation (FCRIS-IFI-2018 and FCRIS-2021-0090), the Fundación Caixa-Health Research (HR21-00761 project IL7R_LungCan), and the Comunidad de Madrid (P2022/BMD-7225 NEXT_GEN_CART_MAD-CM). Work in the DS laboratory was funded by the CNIC; the European Union's Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091; MCIN/AEI/10.13039/501100011033 (PID2019-108157RB); Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); Atresmedia (Constantes y Vitales prize); Fondo Solidario Juntos (Banco Santander); and “La Caixa” Foundation (LCF/PR/HR20/00075). The CNIC was supported by the ISCIII, the MCIN and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MCIN/AEI/10.13039/501100011033). Research in RD laboratory was supported by the ISCIII (PI2100989) and CIBERINFEC; the European Commission Horizon 2020 Framework Programme (grant numbers 731868 project VIRUSCAN FETPROACT-2016, and 101046084 project EPIC-CROWN-2); and the Fundación Caixa-Health Research (grant number HR18-00469 project StopEbola). Research in CNB-CSIC laboratory was funded by Fondo Supera COVID-19 (Crue Universidades-Banco Santander) grant, CIBERINFEC, and Spanish Research Council (CSIC) grant 202120E079 (to J.G.-A.), CSIC grant 2020E84 (to M.E.), MCIN/AEI/10.13039/501100011033 (PID2020-114481RB-I00 to J.G-A. and M.E.), and by the European Commission-NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) to J.G.-A. and M.E. Work in the CIB-CSIC laboratory was supported by MCIN/AEI/10.13039/501100011033 (PID2019-104544GB-I00 and 2023AEP105 to CA, and PID2020-113225GB-I00 to F.J.B.). Cryo-EM data were collected at the Maryland Center for Advanced Molecular Analyses which was supported by MPOWER (The University of Maryland Strategic Partnership). I.H.-M. receives the support of a fellowship from la Caixa Foundation (ID 100010434, fellowship code: LCF/BQ/IN17/11620074) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 71367. L.R.-P. was supported by a predoctoral fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates

  • Pérez Ramírez, Patricia
  • Albericio, Guillermo
  • Astorgano, David
  • Flores, Sara
  • Sánchez-Corzo, Cristina
  • Sánchez-Cordón, Pedro J.
  • Luczkowiak, Joanna
  • Delgado, Rafael
  • Casasnovas, José María
  • Esteban, Mariano
  • García-Arriaza, Juan
17 Pág., The constant appearance of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs) has jeopardized the protective capacity of approved vaccines against coronavirus disease-19 (COVID-19). For this reason, the generation of new vaccine candidates adapted to the emerging VoCs is of special importance. Here, we developed an optimized COVID-19 vaccine candidate using the modified vaccinia virus Ankara (MVA) vector to express a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein, containing 3 proline (3P) substitutions in the S protein derived from the beta (B.1.351) variant, termed MVA-S(3Pbeta). Preclinical evaluation of MVA-S(3Pbeta) in head-to-head comparison to the previously generated MVA-S(3P) vaccine candidate, expressing a full-length prefusion-stabilized Wuhan S protein (with also 3P substitutions), demonstrated that two intramuscular doses of both vaccine candidates fully protected transgenic K18-hACE2 mice from a lethal challenge with SARS-CoV-2 beta variant, reducing mRNA and infectious viral loads in the lungs and in bronchoalveolar lavages, decreasing lung histopathological lesions and levels of proinflammatory cytokines in the lungs. Vaccination also elicited high titers of anti-S Th1-biased IgGs and neutralizing antibodies against ancestral SARS-CoV-2 Wuhan strain and VoCs alpha, beta, gamma, delta, and omicron. In addition, similar systemic and local SARS-CoV-2 S-specific CD4+ and CD8+ T-cell immune responses were elicited by both vaccine candidates after a single intranasal immunization in C57BL/6 mice. These preclinical data support clinical evaluation of MVA-S(3Pbeta) and MVA-S(3P), to explore whether they can diversify and potentially increase recognition and protection of SARS-CoV-2 VoCs., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), and Spanish Research Council (CSIC) grant 202120E079 (to JG-A); CSIC grant 2020E84, la Caixa Banking Foundation grant CF01-00008, Ferrovial, and MAPFRE donations (to ME); and Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RB-I00; to JG-A and ME). This research work was also funded by the European Commission-Next Generation EU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A and ME acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). JC acknowledges MCIN and CSIC support (project number 202020E079). RD received grants from ISCIII (FIS PI2100989), the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016: 731868 and Project EPIC-CROWN-2: 101046084), and Fundacioín Caixa-Health Research HR18-00469 (Project StopEbola)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters

  • Abdelnabi, Rana
  • Pérez, Patricia
  • Astorgano, David
  • Albericio, Guillermo
  • Kerstens, Winnie
  • Thibaut, Hendrik Jan
  • Coelmont, Lotte
  • Weynand, Birgit
  • Labiod, Nuria
  • Delgado, Rafael
  • Montenegro, Dolores
  • Puentes, Eugenia
  • Rodríguez, Esteban
  • Neyts, Johan
  • Dallmeier, Kai
  • Esteban, Mariano
  • García-Arriaza, Juan
The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of the virus. In the present study, we describe the enhanced immunogenicity and efficacy elicited in hamsters by a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein [termed MVA-S(3P)]. Hamsters vaccinated with one or two doses of MVA-S(3P) developed high titers of S-binding IgG antibodies and neutralizing antibodies against the ancestral Wuhan SARS-CoV-2 virus and VoC beta, gamma, and delta, as well as against omicron, although with a somewhat lower neutralization activity. After SARS-CoV-2 challenge, vaccinated hamsters did not lose body weight as compared to matched placebo (MVA-WT) controls. Consistently, vaccinated hamsters exhibited significantly reduced viral RNA in the lungs and nasal washes, and no infectious virus was detected in the lungs in comparison to controls. Furthermore, almost no lung histopathology was detected in MVA-S(3P)-vaccinated hamsters, which also showed significantly reduced levels of proinflammatory cytokines in the lungs compared to unvaccinated hamsters. These results reinforce the use of MVA-S(3P) as a vaccine candidate against COVID-19 in clinical trials., The authors declare that this study received funding from Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), Spanish Research Council (CSIC) grant 202120E079, and funds from Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to JG-A), CSIC grant 2020E84, La CaixaImpulse grant CF01-00008, Ferrovial and MAPFRE donations (to ME), a Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RB-I00 to JG-A and ME), and internal funding from KU Leuven (to JN) and the Flemish Research Foundation (FWO) Excellence of Science (EOS) program (No. 40007527; VirEOS2) (to KD and JN). This research work was also funded by the European Commission-Next Generation EU through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A and ME also acknowledge financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection

  • Gómez-Carballa, Alberto
  • Albericio, Guillermo
  • Montoto-Louzao, Julián
  • Pérez, Patricia
  • Astorgano, David
  • Rivero-Calle, Irene
  • Martinón-Torres, Federico
  • Esteban, Mariano
  • Salas, Antonio
  • García-Arriaza, Juan
Unravelling the molecular mechanism of COVID-19 vaccines through transcriptomic pathways involved in the host response to SARS-CoV-2 infection is key to understand how vaccines work, and for the development of optimized COVID-19 vaccines that can prevent the emergence of SARS-CoV-2 variants of concern (VoCs) and future outbreaks. In this study, we investigated the effects of vaccination with a modified vaccinia virus Ankara (MVA)-based vector expressing the full-length SARS-CoV-2 spike protein (MVA-S) on the lung transcriptome from susceptible K18-hACE2 mice after SARS-CoV-2 infection. One dose of MVA-S regulated genes related to viral infection control, inflammation processes, T-cell response, cytokine production and IFN-γ signalling. Down-regulation of Rhcg and Tnfsf18 genes post-vaccination with one and two doses of MVA-S may represent a mechanism for controlling infection immunity and vaccine-induced protection. One dose of MVA-S provided partial protection with a distinct lung transcriptomic profile to healthy animals, while two doses of MVA-S fully protected against infection with a transcriptomic profile comparable to that of non-vaccinated healthy animals. This suggests that the MVA-S booster generates a robust and rapid antigen-specific immune response preventing virus infection. Notably, down-regulation of Atf3 and Zbtb16 genes in mice vaccinated with two doses of MVA-S may contribute to vaccine control of innate immune system and inflammation processes in the lungs during SARS-CoV-2 infection. This study shows host transcriptomic mechanisms likely involved in the MVA-S vaccine-mediated immune response against SARS-CoV-2 infection, which could help in improving vaccine dose assessment and developing novel, well-optimized SARS-CoV-2 vaccine candidates against prevalent or emerging VoCs., This research was funded by Fondo COVID-19 grant COV20/00151 [Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)], Fondo Supera COVID-19 grant MVA-COVID-19 (Crue Universidades-Banco Santander), Spanish Research Council (CSIC) grant 202120E079 and funds from Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to J.G.-A.); CSIC grant 2020E84, La Caixa Banking Foundation grant CF01-00008, Ferrovial, and MAPFRE donations (to M.E.); and Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RB-I00) (to J.G.-A. and M.E.). This study also received support by i) ISCIII: TRINEO: PI22/00162; DIAVIR: DTS19/00049; Resvi-Omics: PI19/01039 (to A.S.), ReSVinext: PI16/01569, Enterogen: PI19/01090 (to F.M.-T.), cofinanciados FEDER, ii) Axencia Galega de Innovación (GAIN): IN607B 2020/08 and IN607A 2023/02 (to A.S.), GEN-COVID (IN845D 2020/23 (to F.M.-T.), IIN607A2021/05 (to F.M.-T.); iii) Agencia Gallega de Conocimiento en Salud (ACIS): BI-BACVIR (PRIS-3, to A.S.), CovidPhy (SA 304 C, to A.S.); and iv) consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; to A.S. and F.M.-T.). This research work was also funded by the European Commission-NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) (to J.G.-A. and M.E.). J.G.-A. and M.E. acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

  • Perdiguero, Beatriz
  • Pérez, Patricia
  • Marcos-Villar, Laura
  • Albericio, Guillermo
  • Astorgano, David
  • Álvarez, Enrique
  • Sin, Laura
  • Gómez, Carmen Elena
  • García-Arriaza, Juan
  • Esteban, Mariano
Although one member of the poxvirus family, variola virus, has caused one of the most devastating human infections worldwide, smallpox, the knowledge gained over the last 30 years on the molecular, virological and immunological mechanisms of these viruses has allowed the use of members of this family as vectors for the generation of recombinant vaccines against numerous pathogens. In this review, we cover different aspects of the history and biology of poxviruses with emphasis on their application as vaccines, from first- to fourth-generation, against smallpox, monkeypox, emerging viral diseases highlighted by the World Health Organization (COVID-19, Crimean-Congo haemorrhagic fever, Ebola and Marburg virus diseases, Lassa fever, Middle East respiratory syndrome and severe acute respiratory syndrome, Nipah and other henipaviral diseases, Rift Valley fever and Zika), as well as against one of the most concerning prevalent virus, the Human Immunodeficiency Virus, the causative agent of Acquired Immunodeficiency Syndrome. We discuss the implications in human health of the 2022 monkeypox epidemic affecting many countries, and the rapid prophylactic and therapeutic measures adopted to control virus dissemination within the human population. We also describe the preclinical and clinical evaluation of the Modified Vaccinia virus Ankara and New York vaccinia virus poxviral strains expressing heterologous antigens from the viral diseases listed above. Finally, we report different approaches to improve the immunogenicity and efficacy of poxvirus-based vaccine candidates, such as deletion of immunomodulatory genes, insertion of host-range genes and enhanced transcription of foreign genes through modified viral promoters. Some future prospects are also highlighted., We thank various agencies for continuous funding support, such as Fondo COVID-19 grant COV20/00151 [Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)], Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander) and Spanish Research Council (CSIC) grant 202120E079 (to JG-A); Red Sida RD16/0025/0002, CSIC grant 2020E84, La CaixaImpulse grant CF01-00008, Ferrovial and MAPFRE donations (to ME); Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grants PID2020-114481RB-I00 (to JG-A and ME) and PID2020-117425RB-C22 (to CEG); and funds from Centro de Investigacio ́n Biome ́dica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to CEG and JG-A). We have also received funding from the European Commission-Next Generation EU through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). We also acknowledge financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses

  • Pérez Ramírez, Patricia
  • Astorgano, David
  • Albericio, Guillermo
  • Flores, Sara
  • Sánchez-Corzo, Cristina
  • Noriega, María A.
  • Sánchez-Cordón, Pedro J.
  • Labiod, Nuria
  • Delgado, Rafael
  • Casasnovas, José María
  • Esteban, Mariano
  • García-Arriaza, Juan
Despite the decrease in mortality and morbidity due to SARS-CoV-2 infection, the incidence of infections due to Omicron subvariants of SARS-CoV-2 remains high. The mutations acquired by these subvariants, mainly concentrated in the receptor-binding domain (RBD), have caused a shift in infectivity and transmissibility, leading to a loss of effectiveness of the first authorized COVID-19 vaccines, among other reasons, by neutralizing antibody evasion. Hence, the generation of new vaccine candidates adapted to Omicron subvariants is of special interest in an effort to overcome this immune evasion. Here, an optimized COVID-19 vaccine candidate, termed MVA-S(3P_BA.1), was developed using a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein from the Omicron BA.1 variant. The immunogenicity and efficacy induced by MVA-S(3P_BA.1) were evaluated in mice in a head-to-head comparison with the previously generated vaccine candidates MVA-S(3P) and MVA-S(3Pbeta), which express prefusion-stabilized S proteins from Wuhan strain and Beta variant, respectively, and with a bivalent vaccine candidate composed of a combination of MVA-S(3P) and MVA-S(3P_BA.1). The results showed that all four vaccine candidates elicited, after a single intramuscular dose, protection of transgenic K18-hACE2 mice challenged with SARS-CoV-2 Omicron BA.1, reducing viral loads, histopathological lesions, and levels of proinflammatory cytokines in the lungs. They also elicited anti-S IgG and neutralizing antibodies against various Omicron subvariants, with MVA-S(3P_BA.1) and the bivalent vaccine candidate inducing higher titers. Additionally, an intranasal immunization in C57BL/6 mice with all four vaccine candidates induced systemic and mucosal S-specific CD4+ and CD8+ T-cell and humoral immune responses, and the bivalent vaccine candidate induced broader immune responses, eliciting antibodies against the ancestral Wuhan strain and different Omicron subvariants. These results highlight the use of MVA as a potent and adaptable vaccine vector against new emerging SARS-CoV-2 variants, as well as the promising feature of combining multivalent MVA vaccine candidates., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), CSIC grant 202120E079, grant CNS2022-135511 funded by the Spanish Ministry of Science, Innovation and Universities (MCIU)/Spanish Research Agency (AEI)/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to promote the consolidation of research, and funds from Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to JG-A); CSIC grant 2020E84, la Caixa Banking Foundation grant CF01-00008, Ferrovial, and MAPFRE donations (to ME); and Spanish MCIU/AEI/10.13039/501100011033 grant PID2020-114481RB-I00 (to JG-A and ME). This research work was also funded by the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A also received grants from the European Commission HORIZON-HLTH-2023-DISEASE-03-18 (Project MARVAX: 101137183 and Project FLAVIVACCINE: 101137006). JG-A and ME also acknowledges financial support from the Spanish AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). JC acknowledges MCIU and CSIC support (project number 202020E079). RD received grants from ISCIII (FIS PI2100989), the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016: 731868 and Project EPIC-CROWN-2: 101046084), and Fundación Caixa-Health Research HR18-00469 (Project StopEbola). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants

  • Cerdán, Lidia
  • Silva, Katixa
  • Rodríguez-Martín, Daniel
  • Pérez, Patricia
  • Noriega, María A
  • Esteban Martín, Ana
  • Gutiérrez-Adán, Alfonso
  • Margolles, Yago
  • Corbera, Juan A
  • Martín-Acebes, Miguel A.
  • García-Arriaza, Juan
  • Fernández-Recio, Juan
  • Fernández, Luis A.
  • Casasnovas, José M.
To generate antibodies (Abs) against SARS-CoV-2 emerging variants, we integrated multiple tools and engineered molecules with excellent neutralizing breadth and potency. Initially, the screening of an immune library identified a nanobody (Nb), termed Nb4, specific to the receptor-binding domain (RBD) of the Omicron BA.1 variant. A Nb4-derived heavy chain antibody (hcAb4) recognized the spike (S) of the Wuhan, Beta, Delta, Omicron BA.1, and BA.5 SARS-CoV-2 variants. A high-resolution crystal structure of the Nb4 variable (VHH) domain in complex with the SARS-CoV-2 RBD (Wuhan) defined the Nb4 binding mode and interface. The Nb4 VHH domain grasped the RBD and covered most of its outer face, including the core and the receptor-binding motif (RBM), which was consistent with hcAb4 blocking RBD binding to the SARS-CoV-2 receptor. In mouse models, a humanized hcAb4 showed therapeutic potential and prevented the replication of SARS-CoV-2 BA.1 virus in the lungs of the animals. In vitro, hcAb4 neutralized Wuhan, Beta, Delta, Omicron BA.1, and BA.5 viral variants, as well as the BQ.1.1 subvariant, but showed poor neutralization against the Omicron XBB.1.5. Structure-based computation of the RBD-Nb4 interface identified three Nb4 residues with a reduced contribution to the interaction with the XBB.1.5 RBD. Site-saturation mutagenesis of these residues resulted in two hcAb4 mutants with enhanced XBB.1.5 S binding and virus neutralization, further improved by mutant Nb4 trimers. This research highlights an approach that combines library screening, Nb engineering, and structure-based computational predictions for the generation of SARS-CoV-2 Omicron-specific Abs and their adaptation to emerging variants., The work was supported by the Ministerio de Ciencia, Innovación yUniversidades [202020E079, 202120E079, 202340E181, CNS2022-135511, PID2020-114481RB-I00, PID2022-143215OB-I00 andPLEC2021-007739]; NextGenerationEU [SGL 2103047, SGL 2103051and SGL 2103053]; HORIZON EUROPE Framework Programme[101130574-ALADDIN], Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional characteristics of plitidepsin as an antiviral treatment against monkeypox virus infection

  • Albericio, Guillermo
  • Rodríguez-Martín, Daniel
  • Avilés, Pablo
  • Cuevas, Carmen
  • Guillén-Navarro, María José
  • Noriega, María A.
  • Flores, Sara
  • Sánchez-Cordón, Pedro J.
  • Astorgano, David
  • Pérez Ramírez, Patricia
  • Esteban, Mariano
  • García-Arriaza, Juan
Monkeypox virus (MPXV), closely related to variola virus, causes mpox, a zoonotic disease traditionally endemic to Central Africa. However, recent outbreaks have increased human transmission of MPXV clades. In 2022, global MPXV spread was linked to clade IIb, whereas in 2024, the more pathogenic clade Ib became predominant. These trends raised concerns about sustained human transmission, prompting the WHO to declare mpox a Public Health Emergency of International Concern. Despite the availability of smallpox vaccines, their protective efficacy against mpox remains limited. Additionally, the limited efficacy of current smallpox antivirals, such as Tecovirimat and Brincidofovir, alongside growing concerns about the emergency of tecovirimat resistance mutants, underscores the need for new therapeutic options. Given these challenges, novel antiviral strategies with different mechanisms of action are urgently needed to control MPXV outbreaks. Plitidepsin, a cyclodepsipeptide drug initially approved for cancer treatment, has demonstrated potent antiviral activity against multiple viruses by targeting eukaryotic elongation factor 1 alpha (eEF1A). Here, we have evaluated the antiviral activity of plitidepsin against MPXV infection. In cultured cells, plitidepsin exhibited strong antiviral effects, with a favorable therapeutic index and low cytotoxicity. In CAST/EiJ mice, a highly susceptible MPXV model, plitidepsin significantly reduced viral replication in the lungs. Additionally, treated mice displayed a marked reduction in inflammatory lung lesions and proinflammatory cytokines, suggesting immunomodulatory effects. These findings indicate plitidepsin as a promising candidate for mpox treatment. Further studies are needed to explore its potential as a standalone or combination therapy, supporting clinical evaluation for mpox treatment., This work was supported by a research agreement with PharmaMar S.A., by grant CNS2022-135511 funded by the Spanish Ministry of Science, Innovation and Universities (MICIU)/Spanish Research Agency (AEI)/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to promote the consolidation of research, by Spanish Research Council (CSIC) grant 202120E079, and by funds from Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to J.G.-A.); by CSIC grant 2020E84 (to M.E.); and by Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RB-I00) (to J.G.-A. and M.E.). DA received an FPI predoctoral research contract (reference PRE2021-099058) associated to the MCIU/AEI/10.13039/501100011033 grant PID2020-114481RB-I00. This research work was also funded by the European Commission-NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) (to J.G.-A. and M.E.). J.G.-A. and M.E. acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712, CEX2023-001386-S). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (SEV-2013-0347)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (SEV-2017-0712)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2023-001386-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structural basis of poxvirus fusion regulation and anti-A16/G9 antibody-mediated neutralization and protection

  • Meola, Annalisa
  • Vernuccio, Riccardo
  • Battini, Leandro
  • Albericio, Guillermo
  • Delgado, Pilar
  • Bamford, Rebecca
  • Pokorny, Laura
  • Broutin, Manon
  • Martínez León, Alejandro
  • Gallien, Sébastien
  • Gil, María
  • Noriega, María A.
  • Guivel-Benhassine, Florence
  • Porrot, Françoise
  • Postal, Jeanne
  • Buchrieser, Julian
  • Hubert, Mathieu
  • Haouz, Ahmed
  • Lafaye, Pierre
  • Esteban, Mariano
  • Hub, Jochen S.
  • Mahévas, Matthieu
  • Chappert, Pascal
  • Mercer, Jason
  • García-Arriaza, Juan
  • Schwartz, Olivier
  • Guardado-Calvo, Pablo
Monkeypox virus (MPXV) is a poxvirus endemic to Central and West Africa with high epidemic potential. Poxviruses enter host cells via a conserved entry-fusion complex (EFC), which mediates viral fusion to the cell membrane. The EFC is a promising therapeutic target, but the absence of structural data has limited the development of fusion-inhibiting treatments. Here, we investigated A16/G9, a subcomplex of the EFC that controls fusion timing. Using cryo-electron microscopy, we showed how A16/G9 interacts with A56/K2, a viral fusion suppressor that prevents superinfection. Immunization with A16/G9 elicited a protective immune response in mice. Using X-ray crystallography, we characterized two neutralizing antibodies and engineered a chimeric antibody that cross-neutralizes several poxviruses more efficiently than 7D11, the most potent antibody targeting the EFC described to date. These findings highlight the potential of A16/G9 as a candidate for subunit vaccines and identify regions of the EFC as targets for antiviral development., Access to Diamond was funded by iNEXT-Discovery/Instruct (PID: 25820, VID: 43499) and funded by the European Union Research and Innovation programme Horizon Europe (ISIDORe—grant agreement number 101046133). The NanoImaging Core Facility at Institut Pasteur is acknowledged for support with sample preparation, image acquisition, and analysis. The NanoImaging Core was created with the help of a grant from the French Government’s Investissements d’Avenir program (EQUIPEX CACSICE - Centre d’analyse de systèmes complexes dans les environnements complexes, ANR-11-EQPX-0008). We also thank the CNB-CSIC animal facility for help and assistance, Marija Backovic for useful discussions on the serpin assay, and Pierre Legrand for facilitating rapid access to Polaris. The P.G.-C. lab is funded by the Institut Pasteur, the National French Research Agency (ANR; ANR-22-CE11-0003 and ANR-24-CE15-6625), and the European Union RESILIENCE-R-2023 (n°101168024). The O.S. lab is funded by Institut Pasteur, Fondation pour la Recherche Médicale (FRM), ANRS, the Vaccine Research Institute (VRI) (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), the HERA projects DURABLE (grant 101102733), and LEAPS. J.P. is supported by DURABLE. The J.G.-A. lab is funded by CSIC grant 202120E079; grant CNS2022-135511 from the Spanish Ministry of Science, Innovation, and Universities (MCIU)/Spanish Research Agency (AEI)/10.13039/501100011033 and the European Union NextGenerationEU/PRTR to promote the consolidation of research; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBER-INFEC), co-financed with FEDER funds; and Spanish MCIU/AEI/10.13039/501100011033 grant . J.G.-A. and M.E. are also funded by the European Union RESILIENCE-R-2023 (n°101168024), funded by the European Union. Views and opinions expressed are those of the author(s) and do not necessarily reflect those of the European Union or the European Defence Fund. Neither the European Union nor the granting authority can be held responsible for them. This is related to the project RESILIENCE-R-2023 (n°101168024). J.S.H. and A.M.L. are funded by the European Union’s Horizon 2020 research and the innovation program under Marie Sklodowska Curie Grant 860592 and Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; grants SFB1027/B7 and INST256/539-1). The P.C. and M.M. lab is funded by the National French Research Agency (ANR-24-CE15-6625 and France 2030 funding ANR-24-CHBS-0003). L.P. was supported by the UCL Birkbeck MRC DTP. R.B. was funded by the MRC Laboratory for Molecular Cell Biology PhD program. J.M. was supported by the MRC Laboratory for Molecular Cell Biology (MC_UU_00012/7)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters

  • Pérez, Patricia
  • Jiang, Kaijun
  • González-Domínguez, Irene
  • Rodríguez-Martín, Daniel
  • Abdeljawad, Adam
  • Cupic, Anastasija
  • Slamanig, Stefan
  • Flores, Sara
  • Noriega, María A
  • Sánchez-Cordón, Pedro J.
  • Lemus, Nicholas
  • Lai, Tsoi Ying
  • Sun, Weina
  • Esteban, Mariano
  • García-Sastre, Adolfo
  • García-Arriaza, Juan
Effective vaccination strategies adaptable to emerging viruses like SARS-CoV-2 and capable of inducing robust protective immunity are needed. We evaluated the immunogenicity and protective efficacy of homologous and heterologous prime/boost regimens against SARS-CoV-2 in K18-hACE2 mice and Syrian hamsters using Newcastle disease virus (NDV-HXP-S, intranasal) and modified vaccinia virus Ankara (MVA-S(3P), intramuscular) vectors encoding a prefusion-stabilized SARS-CoV-2 spike (S) protein. All regimens protected against weight loss and markedly reduced viral replication and lung pathology. Vaccination induced serum anti-S and anti-receptor binding domain IgGs and neutralizing antibodies against ancestral virus and variants. In mice, mucosal anti-S IgA and IgG were detected after NDV-HXP-S immunization. Homologous MVA-S(3P)/MVA-S(3P) and heterologous NDV-HXP-S/MVA-S(3P) elicited higher polyfunctional systemic T-cell responses, while homologous NDV-HXP-S/NDV-HXP-S induced stronger pulmonary CD8+ T cells. Hamsters vaccinated with NDV-HXP-S exhibited protection of the upper respiratory tract, with the NDV-HXP-S/MVA-S(3P) regimen showing a trend toward reduced direct contact transmission of SARS-CoV-2. These findings demonstrate the capacity of NDV and MVA vector platforms to induce robust systemic and mucosal antigen-specific humoral and T-cell responses against SARS-CoV-2, contributing to protection against both disease and transmission, and support further exploration of these vector platforms for vaccination against SARS-CoV-2 and potentially other pathogens., This research was supported by CSIC grant 202120E079, grant funded by the Spanish Ministry of Science, Innovation and Universities (MCIU)/Spanish Research Agency (AEI)/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to promote the consolidation of research, and funds from Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to J.G.-A.); CSIC grant 2020E84 (to M.E.); Spanish MCIU/AEI/10.13039/501100011033 grant PID2020-114481RB-I00 (to J.G.-A. and M.E.). This work was also partly supported by CRIPT (Center for Research on Influenza Pathogenesis and Transmission), an NIAID-funded Center of Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014) (to A.G.-S.). This works is also supported by seed funding awarded by ISMMS Department of Microbiology (to W.S.). This research work was also funded by the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to J.G.-A. and M.E.). J.G.-A. also received grants from the European Commission HORIZON-HLTH-2023-DISEASE-03-18 (Project MARVAX: 101137183 and Project FLAVIVACCINE: 101137006). J.G.-A. and M.E. also acknowledges financial support from the Spanish AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2017-0712, CEX2023-001386-S). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Eeyarestatin I, an inhibitor of the valosin-containing protein, exhibits potent virucidal activity against the flaviviruses

  • Rodrigo, Imanol
  • Ballesta, Carlos
  • Nunes, Eliane Blanco
  • Pérez, Patricia
  • García-Arriaza, Juan
  • Arias, Armando
Cellular responses to stress generally lead to the activation of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Several lines of study support that ERAD may be playing a proviral role during flaviviral infection. A key host factor in ERAD is the valosin-containing protein (VCP), an ATPase which ushers ubiquitin-tagged proteins to degradation by the proteasome. VCP exhibits different proviral activities, such as engaging in the biogenesis of viral replication organelles and facilitating flavivirus genome uncoating after the viral particle entry. To investigate the possible antiviral value of drugs targeting VCP, we tested two inhibitors: eeyarestatin I (EEY) and xanthohumol (XAN). Both compounds were highly effective in suppressing Zika virus (ZIKV) and Usutu virus (USUV) replication during infection in cell culture. Further analysis revealed an unexpected virucidal activity for EEY, but not for XAN. Preincubation of ZIKV or USUV with EEY before inoculation to cells resulted in significant decreases in infectivity in a dose- and time-dependent manner. Viral genomes in samples previously treated with EEY were more sensitive to propidium monoazide, an intercalating agent, with 10- to 100-fold decreases observed in viral RNA levels, supporting that EEY affects viral particle integrity. Altogether, these results support that EEY is a strong virucide against two unrelated flaviviruses, encouraging further studies to investigate its potential use as a broad-acting drug or the development of improved derivatives in the treatment of flaviviral infection., This research was funded by Ministerio de Ciencia, Innovación y Universidades (MICIU) of Spain, grant number PID2019-106068 GB-I00, and by Junta de Comunidades de Castilla-La Mancha, grant number SBPLY/21/180501/000076. Part of this research was also funded by Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), Spanish Research Council (CSIC) grant 202120E079, and Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant PID2020-114481RB-I00 to JG-A. AA is the recipient of a Beatriz Galindo Senior Fellowship (BEAGAL18/00074) from MICIU. IR has been supported by a predoctoral fellowship (2020-PREDUCLM-16723) and CB by a Beca CRIB Iniciación 2021 (BII2021/01), both granted by UCLM., Peer reviewed, Sin uso de modelos vivos
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-2

  • Pérez, Patricia
  • Esteso, Gloria
  • Noriega, María A.
  • Vidakovics, Laura Perez
  • Liljeström, Peter
  • McInerney, Gerald M
  • Esteban, Mariano
  • García-Arriaza, Juan
Despite the success of current COVID-19 vaccines, the immunity they generate wanes over time, requiring periodic boosters. The limited durability of memory responses, particularly from mRNA vaccines, remains a major challenge for achieving long-term protection. Developing vaccines that induce more sustained immunity would lessen the need for frequent revaccination, improving global vaccination logistics, especially in resource-limited settings. DNA-launched self-amplifying RNA replicons (DREP) and modified vaccinia virus Ankara (MVA) vectors are promising vaccine platforms capable of inducing potent humoral and cellular immunity. In this study, we evaluated SARS-CoV-2-specific immune responses in C57BL/6 mice following homologous and heterologous prime/boost regimens combining DREP- and MVA-based vaccines expressing the spike (S) protein from either the ancestral Wuhan strain or the Omicron XBB.1.5 variant. Homologous (DREP/DREP, MVA/MVA) and heterologous (DREP/MVA) regimens were followed for six months. MVA-S(3P)-based boosters elicited robust and durable anti-S IgG antibodies cross-recognizing multiple variants, with minimal decay over time. Neutralization mapped to the booster antigen: MVA-S(3PWuhan) induced neutralization of the ancestral strain, while MVA-S(3PXBB.1.5) selectively neutralized Omicron subvariants, maintaining high titers for at least six months. MVA-S(3P) boosters also enhanced antibody Fc-effector functions, memory B cells, and T follicular helper responses. Early after boosting, heterologous DREP/MVA regimens induced stronger CD4⁺ and CD8⁺ T-cell responses, while at six months all MVA-S(3P)-boosted groups maintained superior, long-lived cellular immunity. Collectively, MVA-S(3P)-based boosters improved the magnitude, breadth, and durability of humoral and cellular responses, supporting their strategic use in homologous and heterologous DREP/MVA vaccination regimens against SARS-CoV-2 and emerging variants., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by CSIC grant 202120E079, grant CNS2022-135511 funded by the Spanish Ministry of Science, Innovation and Universities (MCIU)/Spanish Research Agency (AEI)/https://doi.org/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to promote research consolidation, as well as funds from the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with FEDER funds (to JG-A). Additional support was provided by CSIC grant 2020E84 (to ME), and by Spanish MCIU/AEI/https://doi.org/10.13039/501100011033 grant PID2020-114481RB-I00 (to JG-A and ME). This research work also received funding from the European Commission-NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A received further funding from the European Commission HORIZON-HLTH-2023-DISEASE-03-18 (Project MARVAX: 101137183 and Project FLAVIVACCINE: 101137006). JG-A and ME also acknowledge financial support from the Spanish AEI/https://doi.org/10.13039/501100011033 through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2017-0712, CEX2023-001386-S). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication., Peer reviewed, Modelo experimental animal, Mamíferos - Roedores